We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New Biomimicry Control for COVID Diagnostics Improves Accuracy and Safety of Coronavirus Testing

By LabMedica International staff writers
Posted on 03 Nov 2020
Print article
Image: New Biomimicry Control for COVID Diagnostics Improves Accuracy and Safety of Coronavirus Testing (Photo courtesy of Wits University)
Image: New Biomimicry Control for COVID Diagnostics Improves Accuracy and Safety of Coronavirus Testing (Photo courtesy of Wits University)
A team of researchers have developed a unique “control standard” that improves accuracy and safety of COVID-19 testing by using biomimicry as a safer alternative to incorporating the actual SARS-COV-2 virus.

Researchers at the Centre for Biomedical Tuberculosis Research at Wits University (Johannesburg, South Africa) have used the biomimicry technique to engineer a control organism that mimics the genetic material of the virus, when used in diagnostic tests kits. If the tests work correctly, the genetically modified organism is identified as being SARS-CoV-2. The control is a safe, non-pathogenic (non-disease causing), and stable. It can be rapidly deployed in a range of settings - from central laboratories to clinics. In contrast, viral-based controls require specialist shipping and handling procedures, and the need for highly-skilled staff and infrastructure.

Accuracy of testing controls is central to the deployment of any successful diagnostic test. The new control aims to fill the gap in the verification of COVID-19 tests obtained via molecular diagnosis tools, and reduce the risks and complications of using the live virus.

“The virus continues to spread viciously across countries, with infections again rising rapidly across Europe and North America,” said Professor Bavesh Kanawho headed the Wits team. “In order for governments to halt its spread, reliable tools with verifiable results are of utmost importance. Without appropriate controls to report whether tests are delivering the correct result diagnosing and effectively managing COVID-19 will be very difficult, if not impossible.”

Related Links:
Wits University

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
SARS-CoV-2 Test
One Step SARS-CoV-2 Nucleic Acid Detection Kit (P761H)

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The revolutionary autonomous blood draw technology is witnessing growing demands (Photo courtesy of Vitestro)

Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing

Blood drawing is performed billions of times each year worldwide, playing a critical role in diagnostic procedures. Despite its importance, clinical laboratories are dealing with significant staff shortages,... Read more